All In Biotech

Drug Trial Radar · NCT00514514

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Multi-center, Open-label, Prospective, Randomized, Parallel Group, Long-term Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a CNI-free Regimen and a CNI-low Dose Regimen

Last checked: Nov 20, 2026Latest source record: Jan 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 802 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

802

Actual

Start

Jul 2007

Primary completion

Jun 2015

Study completion Jun 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 10, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare renal function of immunosuppressive regimens with different relevance of the calcineurin inhibitor (CNI) cyclosporine: standard dose CNI, low dose CNI, CNI free in de novo kidney transplant patients after 12 months of therapy.

Conditions

  • Kidney Transplantation

Interventions

  • EverolimusDrug

    Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen

  • MyforticDrug

    1 tablet containing 180 mg or 360 mg Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)

  • Sandimmun OptoralDrug

    1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level

  • Simulect®Drug

    Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard RegimenTime frame: From randomization at BL2 (Month 3) to Month 12 post-transplant

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hannover Muenden, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Kaiserslautern, Germany

  • Novartis Investigative Site

    Lübeck, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Regensburg, Germany

  • Novartis Investigative Site

    Bern, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.